Trends in blood pressure control in US adults with hypertension, 2013-2014 to 2021-2023

Shakia T Hardy; Byron C Jaeger; Kathryn Foti; Lama Ghazi; Gregory Wozniak; Paul Muntner

doi:10.1093/ajh/hpae141

Trends in blood pressure control in US adults with hypertension, 2013-2014 to 2021-2023

Am J Hypertens. 2024 Nov 6:hpae141. doi: 10.1093/ajh/hpae141. Online ahead of print.

Authors

Shakia T Hardy¹, Byron C Jaeger², Kathryn Foti³, Lama Ghazi³, Gregory Wozniak⁴, Paul Muntner^{3

5}

Affiliations

¹ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
² Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC.
³ Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
⁴ American Medical Association, Chicago, IL.
⁵ Perisphere Real World Evidence, Austin, TX.

PMID: 39504487
DOI: 10.1093/ajh/hpae141

Abstract

Background: Prior studies have reported a decrease in the proportion of US adults with hypertension that had controlled blood pressure (BP).

Methods: We analyzed data from the National Health and Nutrition Examination Survey (n=25,128, ≥18 years of age) to determine changes in BP control from 2013-2014 to 2021-2023. Hypertension was defined as systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg or antihypertensive medication use. BP control was defined as systolic BP <140 mmHg and diastolic BP <90 mmHg.

Results: The age-adjusted prevalence of hypertension (95%CI) was 32.8% (31.2%-34.4%) in 2013-2014 and 32.0% (30.1%-33.9%) in 2021-2023. Among US adults with hypertension, the age-adjusted proportion (95%CI) with controlled BP was 54.1% (49.1%-59.2%), 48.6% (44.5%-52.7%), and 48.3% (45.8%-50.8%) in 2013-2014, 2015-2016 and 2017-2020, respectively (p-trend=0.058), and 51.1% (47.9%-54.3%) in 2021-2023 (p-value=0.184 comparing 2021-2023 versus 2017-2020). The proportion (95%CI) of US adults taking antihypertensive medication with controlled BP was 72.0% (68.5%-75.5%), 66.7% (62.9%-70.5%), and 67.8% (65.3%-70.3%) in 2013-2014, 2015-2016, and 2017-2020, respectively (p-trend=0.085), and 68.3% (64.8%-71.9%) in 2021-2023 (p-value=0.654 comparing 2021-2023 versus 2017-2020). Among non-Hispanic Black adults, BP control increased from 37.4% (95%CI 33.6%-41.1%) to 49.6% (95%CI 42.3%-56.9%) between 2017-2020 and 2021-2023 for those with hypertension (p-value=0.005), and from 52.6% (95%CI 47.4%-57.8%) to 62.6% (95%CI 55.6%-69.7%) for those taking antihypertensive medication (p-value=0.033). There was no difference in BP control across race/ethnicity groups in 2021-2023.

Conclusions: The decline in BP control from 2013-2014 to 2017-2020 did not continue through 2021-2023. An increase in BP control occurred from 2017-2020 and 2021-2023 among non-Hispanic Black adults.

Keywords: Hypertension; antihypertensive medication; blood pressure; prevalence; trends.

Abstract

Grants and funding